J. Yu

发表

The Delayed Nephrogram: Point-of-care Quantitative Measurement, Validation as an Indicator of Obstruction, and Novel Use as a Predictor of Renal Functional Impairment.

R. Uzzo, David Y. T. Chen, A. Kutikov, 2022, European urology focus.

Immune Checkpoint Inhibitor Therapy in Neuroendocrine Tumors

J. Klubo-Gwiezdzinska, J. Yu, Sriram Gubbi, 2022, Hormone and Metabolic Research.

Response of an ERBB2-mutated inflammatory breast carcinoma to human epidermal growth factor receptor 2-targeted therapy.

P. Stephens, D. Lipson, V. Miller, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma.

A. D. Van den Abbeele, A. LaCasce, M. Millenson, 2012, Blood.

Evaluation of the Anti-HER2 C6.5 Diabody as a PET Radiotracer to Monitor HER2 status and Predict Response to Trastuzumab Treatment

J. Marks, M. Robinson, J. Yu, 2010, Clinical Cancer Research.

PET/CT in Patients with Sarcoidosis or IgG4 Disease.

H. Zhuang, I. Codreanu, J. Yu, 2012, PET clinics.

Targeted and Functional Imaging

A. Alavi, D. Torigian, J. Yu, 2015 .

Linsitinib (OSI-906) for the Treatment of Adult and Pediatric Wild-Type Gastrointestinal Stromal Tumors, a SARC Phase II Study

A. D. Van den Abbeele, J. Crowley, D. Flieder, 2019, Clinical Cancer Research.

COVID-19 Vaccine-Related Local FDG Uptake.

J. Yu, M. Doss, J. Yu, 2021, Clinical nuclear medicine.

Multicenter Trial of [18F]fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Staging of Head and Neck Cancer and Negative Predictive Value and Surgical Impact in the N0 Neck: Results From ACRIN 6685.

V. Lowe, J. Sicks, T. Bartel, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Biodistribution and Radiation Dosimetry of the Carbonic Anhydrase IX Imaging Agent [18 F]VM4-037 Determined from PET/CT Scans in Healthy Volunteers

Zhihong Zhu, David Y. T. Chen, R. Alpaugh, 2014, Molecular Imaging and Biology.

Potential role of 124I-girentuximab in the presurgical diagnosis of clear-cell renal cell cancer

E. Plimack, David Y. T. Chen, M. Smaldone, 2012, Biologics : targets & therapy.

Molecular Imaging for Renal Cell Carcinoma

Jian Yu, J. Yu, Y. Dou, 2019, Renal Cancer.

Biodistribution and Radiation Dosimetry of the Integrin Marker 18F-RGD-K5 Determined from Whole-Body PET/CT in Monkeys and Humans

E. Hostetler, M. von Mehren, R. Alpaugh, 2012, The Journal of Nuclear Medicine.

False-Positive Scalp Activity in 131I Imaging Associated with Hair Coloring

D. Yan, R. Mehra, R. Parsons, 2013, The Journal of Nuclear Medicine Technology.

The Role of Qualitative and Quantitative Analysis of F18-FDG Positron Emission Tomography in Predicting Pathologic Response Following Chemoradiotherapy in Patients with Esophageal Carcinoma

N. Meropol, Tianyu Li, Jonathan D. Cheng, 2012, Journal of Gastrointestinal Cancer.

Selective CDK 4 / 6 inhibition with tumor responses by PD 0332991 in patients with mantle cell lymphoma *

A. LaCasce, M. Millenson, J. Leonard, 2012 .

Utility of preoperative ferumoxtran-10 MRI to evaluate retroperitoneal lymph node metastasis in advanced cervical cancer: Results of ACRIN 6671/GOG 0233

M. Gee, M. Harisinghani, S. Raman, 2014, European journal of radiology open.

Circulating Tumor Cells and PET

M. Cristofanilli, J. Yu, J. Yu, 2011, The Journal of Nuclear Medicine.

Biodistribution and Radiation Dosimetry of 18F-CP-18, a Potential Apoptosis Imaging Agent, as Determined from PET/CT Scans in Healthy Volunteers

Mohan Doss, Hartmuth C. Kolb, Joseph C. Walsh, 2013, The Journal of Nuclear Medicine.

Integration of modern imaging into the multidisciplinary setting: The radiation oncology perspective

S. Feigenberg, C. Campassi, J. Yu, 2012, Applied Radiology.

Biodistribution and radiation dosimetry of the hypoxia marker 18F–HX4 in monkeys and humans determined by using whole-body PET/CT

E. Hostetler, K. Alpaugh, H. Kolb, 2010, Nuclear medicine communications.

Lymphoma Causing Gastrosplenic Fistula Revealed by FDG PET/CT.

J. Tokar, S. Barta, J. Yu, 2017, Clinical nuclear medicine.

Normal Variants and Pitfalls Encountered in PET Assessment of Gynecologic Malignancies.

R. Alpaugh, J. Yu, M. Doss, 2018, PET clinics.

An unusual site of metastasis from gastrointestinal stromal tumor

M. von Mehren, J. Trent, J. Yu, 2010, Rare tumors.

Potential role of 124 I-girentuximab in the presurgical diagnosis of clear-cell renal cell cancer

E. Plimack, David Y. T. Chen, M. Smaldone, 2012 .

NRG Oncology HN006: Randomized phase II/III trial of sentinel lymph node biopsy versus elective neck dissection for early-stage oral cavity cancer.

Steven S. Chang, V. Lowe, S. Kappadath, 2021 .

Antitumor response of an ERBB2 amplified inflammatory breast carcinoma with EGFR mutation to the EGFR-TKI erlotinib.

P. Stephens, J. Ross, D. Lipson, 2014, Clinical breast cancer.

Impact of expression system on the function of the C6.5 diabody PET radiotracer

K. Chester, B. Tolner, M. Robinson, 2012, Tumor Biology.

Clinical Performance of Technetium-99m–Sestamibi SPECT/CT Imaging in Differentiating Oncocytic Tumors From Renal Cell Carcinoma in Routine Clinical Practice

E. Handorf, David Y. T. Chen, A. Kutikov, 2023, The Journal of urology.

Cdk4/6 Inhibitor PD 0332991 Demonstrates Cell Cycle Inhibition Via FLT-PET Imaging and Tissue Analysis in Patients with Recurrent Mantle Cell Lymphoma

A. LaCasce, J. Leonard, S. Larson, 2008 .

Cerenkov Luminescence Imaging as a Modality to Evaluate Antibody-Based PET Radiotracers

Mohan Doss, M. Robinson, M. Torgov, 2017, The Journal of Nuclear Medicine.

Cerenkov Luminescence Imaging as a Modality to Evaluate Antibody-based Positron Emission Tomography Radiotracers

M. Robinson, M. Torgov, Jimson W D'souza, 2016 .